Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements
11/09/2022 - 12:38 PM
NEW YORK Nov. 9, 2022 biopharmaceutical company, November 9, 2022 , informing the Company that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on the NASDAQ Capital Market.
On December 30, 2021 , NASDAQ notified the Company that its common stock failed to maintain a minimum bid price of $1.00 October 26 through November 8, 2022 , the closing bid price of the Company's common stock has been at $1.00
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to develop innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate medications that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/
Investor Contact: investorrelations@hoththerapeutics.com www.hoththerapeutics.com
https://www.prnewswire.com/news-releases/hoth-therapeutics-regains-compliance-with-nasdaq-listing-requirements-301673351.html
SOURCE Hoth Therapeutics, Inc.
HOTH Rankings
N/A Ranked by Stock Gains
HOTH Stock Data
Industry
Medicinal and Botanical Manufacturing
Sector
Manufacturing
Tags
Pharmaceuticals: Major, Health Technology, Manufacturing, Medicinal and Botanical Manufacturing
About HOTH
hoth therapeutics, inc., a biopharmaceutical company, focuses on developing therapies for dermatological disorders. the company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. it intends to use the biolexa platform to develop two topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures. the company has license agreements with the george washington university; the university of maryland baltimore; isoprene pharmaceuticals, inc.; the north carolina state university; chelexa biosciences, inc.; and the university of cincinnati. it also has a partnership agreement with zyl㶠therapeutics inc. co-develop a new topical treatment for patients with cutaneous lupus erythematosu, a chronic autoimmune disease that affects the skin and is associated with a significant burden on patient quality of life. hoth therapeutics has research collaboratio
